A Phase 4 interventional study of Nicorandil in Coronary Artery Disease and End Stage Renal Disease, sponsored by Kumamoto University. Active, not recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Kumamoto University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Coronary Artery Disease with a site in Japan — 12 open to participants now, 21 under way, 2 of them phase 3. Coronary Artery Disease · Japan.
Among the 134 studies in Coronary Artery Disease with a site in Japan, this one is the 54th largest by enrollment of the 100 interventional ones that give a count, is one of 4 that started in 2008, is one of 36 in phase 4, reaches primary completion later than 0 of the 20 other live ones, and was the 45th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →12 of the 134 studies in Coronary Artery Disease with a site in Japan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Japan, United States, Australia and 2 more countries
Ages 18–80
Medtronic Vascular · Sites in Japan, United States, Canada and 6 more countries
Ages 18+
CSL Behring · Sites in Japan, United States, Argentina and 32 more countries
Ages 18+
Seung-Jung Park · Sites in Japan, Hong Kong, India and 2 more countries
Ages 20+
Weill Medical College of Cornell University · Sites in Japan, United States, Australia and 23 more countries
Ages 18+ · Women only
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 17 · Phase 4 36
First in 1996; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 268 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 445 across the 100 interventional studies, 431 across the 34 observational. Of the 91 that completed or were terminated, 36 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 134 have an industry lead sponsor. The 10 most frequent:
Kumamoto University is the lead sponsor of 23 studies on the registry; 1 is open to participants now.
Kumamoto University has 8 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Coronary Artery Disease with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT06535854Medtronic VascularPrevail Global Study | 2027-02 |
| NCT05829889Seung-Jung ParkFractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease | 2027-06 |
| NCT07830719Novartis PharmaceuticalsDose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP | 2027-08-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 134 studies in Coronary Artery Disease with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Nicorandil is potentially effective to prevent cardiovascular events in patients with coronary artery disease (CAD) receiving hemodialysis. The purpose of this study is to prospectively investigate whether nicorandil is effective in reducing the incidence of cardiovascular events in patients with CAD on hemodialysis.
Patients on hemodialysis for end-stage renal disease are at high risk for death from ischemic heart disease. It was reported that nicorandil, a hybrid compound on adenosine triphosphate-sensitive potassium channel opener and nitric oxide door, was potentially effective to prevent cardiovascular events in patients with CAD receiving hemodialysis. Therefore, investigators prospectively examine whether nicorandil is effective in reducing the incidence of cardiovascular events in patients with CAD on hemodialysis.
The primary endpoint is a composite of cardiovascular death, sudden cardiac death, nonfatal myocardial infarction, hospitalization for recurrent symptomatic myocardial ischemia and stroke. The secondary endpoints are total mortality, revascularization therapy, hospitalization for heart failure, hospitalization for peripheral artery disease and newly onset of atrial fibrillation.
Patient population that needs to prove the hypothesis is estimate to be 400 cases in total (200 cases in each group). Investigators set the parameters which are need to calculate the number of study patients as follows; drop out rate 10%, an event rate of the primary end point for two years 50%, a risk reduction rate brought by nicorandil 60%, a statistical power 80% and two-sided significant level 0.05. Investigators referred the event rate and the risk reduction rate from the previous study by Ishi H et al. In this study, event rate of the primary end point for two years was 50% and the risk reduction brought by nicorandil was 60%. Event rate of the present study will be lower, because drug-eluting stents are widely used to prevent restenosis in the present era. Moreover, investigators include the patients underwent coronary bypass graft in the present study. In addition, non-cardiovascular mortality is high in the patients on hemodialysis. Considering all the various factors together, investigators estimated the study sample size.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligible patients are who meet the following criteria:
Exclusion Criteria:
Nicorandil was administered orally (15mg/day).
Drug: Nicorandil
Nicorandil was not administered.
15mg per day
Also known as: Sigmart
The primary endpoint is composite of :1) cardiovascular death 2)sudden cardiac death 3)nonfatal myocardial infarction 4)Hospitalization for recurrent symptomatic myocardial ischemia 5)stroke
Time frame: 2 years
Total mortality
Time frame: 2 years
revascularization therapy
Time frame: 2 years
hospitalization for heart failure
Time frame: 2 years
hospitalization for peripheral artery disease
Time frame: 2 years
newly onset of atrial fibrillation
Time frame: 2 years
Plan to share: Undecided
The record gives a start of Jun 2008, a primary completion of Jun 2011 and a completion of Aug 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nicorandil
Kumamoto University